Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 10/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.54 |
| ▸ | NPY1R | P25929 | 5/20 | 0.54 |
| ▸ | NPY2R | P49146 | 3/20 | 0.54 |
| ▸ | CTSG | P08311 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552216 | 0.93 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6046817 | 0.93 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6046826 | 0.93 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6046841 | 0.84 | NPY4R (0.51) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6046837 | 0.83 | NPY4R (0.48) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6805280 | 0.81 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL7440667 | 0.79 | NPY4R (0.58) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6664909 | 0.78 | FOLH1 (0.53) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6046846 | 0.78 | NPY4R (0.45) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL16299120 | 0.78 | NPY4R (0.58) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160741-A1 | Dimeric TF antagonists | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1485476-A2 | DIMERIC TF ANTAGONIST | NOVO NORDISK A/S (DK) | 2004-12-15 | — | — | EP | claimed |
| US-20030229018-A1 | Dimeric TF antagonist | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | claimed |
| WO-2003076461-A2 | DIMERIC TF ANTAGONIST COMPRISING TWO FACTOR VII POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2003-09-18 | — | — | WO | claimed |
| US-20060160741-A1 | Dimeric TF antagonists | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1485476-A2 | DIMERIC TF ANTAGONIST | NOVO NORDISK A/S (DK) | 2004-12-15 | — | — | EP | disclosed |
| US-20030229018-A1 | Dimeric TF antagonist | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003076461-A2 | DIMERIC TF ANTAGONIST COMPRISING TWO FACTOR VII POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160741-A1 | Dimeric TF antagonists | TFPI, TFPI2, F2 | NPY4R 2562/4885NPY5R 2366/4885NPY1R 1684/4885 |
| US-20030229018-A1 | Dimeric TF antagonist | F2, TFPI, TFPI2 | NPY4R 2038/4885NPY5R 1852/4885NPY1R 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.